Inhibrx Biosciences Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, concentrating on the advancement of biological therapeutics intended for individuals facing life-threatening illnesses. The company was established in 2024, following a strategic spin-off that allowed its oncology and rare disease assets, distinct from INBRX-101, to continue independent development after the acquisition of Inhibrx, Inc. by Sanofi. Its development pipeline features ozekibart (INBRX-109), a precisely engineered tetravalent death receptor 5 (DR5) agonist, which recently reported positive topline data from its registrational Phase 2 study for the treatment of unresectable or metastatic conventional chondrosarcoma, with a Biologics License Application planned for the second quarter of 2026. Additional investigations for INBRX-109 include Phase 1 trials for Ewing sarcoma and colorectal cancer. Also in its pipeline is INBRX-106, a novel hexavalent OX40 agonist, currently undergoing a seamless Phase 2/3 randomized study in combination with pembrolizumab for first-line recurrent or metastatic head and neck squamous cell carcinoma, alongside other solid tumor evaluations in earlier phase trials. Leveraging proprietary protein engineering platforms, Inhibrx Biosciences focuses on creating multivalent therapeutic candidates designed to optimize target-specific agonist functions. The company is headquartered in La Jolla, California.
Company News
Inhibrx Announces Participation in Upcoming Scientific Conferences
Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% on Insider Buying Activity
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 3.7% Following Insider Buying Activity
Inhibrx Biosciences (NASDAQ:INBX) Stock: Insider Jon Faiz Kayyem Buys 5,000 Shares
Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) Director Purchases $500,000.00 in Stock
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
Inhibrx Reports Second Quarter 2026 Financial Results
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
Inhibrx Reports First Quarter 2026 Financial Results